Vertex executive reports tax-withheld share disposition

Vertex Pharmaceuticals executive Amit Sachdev reported a tax-related share disposition.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Amit Sachdev reported a tax-related share disposition. On 02/10/2026, 2,057 shares of Vertex common stock were disposed of in a tax-withholding transaction at $468.41 per share. After this, he held 68,941 shares directly.

He also reported indirect ownership of 882 shares through a 401(k) plan and 9,301 shares held in a trust. The filing reflects equity compensation and related tax withholding rather than an open-market trade.

Insider Trade Summary

Exercise Price or Tax Liability: 2,057 shares

Exercise Price or Tax Liability 3 txns

Insider Sachdev Amit

Role EVP Chief Patient & Ext Af Off

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	2,057	$468.41	$964K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 68,941 shares (Direct); Common Stock — 882 shares (Indirect, 401(k)); Common Stock — 9,301 shares (Indirect, Held in Trust)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vertex (VRTX) report for Amit Sachdev?

Amit Sachdev reported a tax-withholding share disposition. On 02/10/2026, 2,057 Vertex common shares were disposed of at $468.41 per share to satisfy tax obligations tied to equity compensation, rather than through an open-market purchase or sale.

How many Vertex (VRTX) shares does Amit Sachdev own after the reported transaction?

After the transaction, Amit Sachdev directly owned 68,941 shares. The Form 4 also shows indirect ownership of 882 shares through a 401(k) plan and 9,301 shares held in a trust, reflecting both direct and indirect stakes in Vertex.

What does the Form 4 transaction code F mean for Vertex (VRTX)?

Transaction code F indicates a tax-withholding disposition. In this case, 2,057 Vertex common shares were used to pay the exercise price or tax liability associated with equity compensation, rather than being voluntarily sold on the open market.

What is Amit Sachdev’s role at Vertex (VRTX) in this Form 4 filing?

Amit Sachdev is an officer of Vertex Pharmaceuticals. The filing lists him as EVP Chief Patient & Ext Af Off, indicating an executive position with responsibilities related to patient and external affairs, and subject to insider reporting requirements under Section 16.

Does the Vertex (VRTX) Form 4 show indirect share ownership for Amit Sachdev?

Yes, the Form 4 shows indirect ownership positions. In addition to 68,941 directly held shares, the filing reports 882 Vertex shares held through a 401(k) plan and 9,301 shares held in a trust as indirect beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 05:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sachdev Amit

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Chief Patient & Ext Af Off

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		F		2,057	D	$468.41	68,941	D
Common Stock								882	I	401(k)
Common Stock								9,301	I	Held in Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.